Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 113

1.

Oral topotecan for refractory and relapsed neuroblastoma: a retrospective analysis.

Kramer K, Kushner BH, Cheung NK.

J Pediatr Hematol Oncol. 2003 Aug;25(8):601-5.

PMID:
12902911
2.
3.

Topotecan by 21-day continuous infusion in children with relapsed or refractory solid tumors: a Children's Oncology Group study.

Hawkins DS, Bradfield S, Whitlock JA, Krailo M, Franklin J, Blaney SM, Adamson PC, Reaman G.

Pediatr Blood Cancer. 2006 Nov;47(6):790-4.

PMID:
16435380
4.

A phase II study of topotecan with vincristine and doxorubicin in children with recurrent/refractory neuroblastoma.

Garaventa A, Luksch R, Biasotti S, Severi G, Pizzitola MR, Viscardi E, Prete A, Mastrangelo S, Podda M, Haupt R, De Bernardi B.

Cancer. 2003 Dec 1;98(11):2488-94.

5.

Gefitinib in combination with oral topotecan and cyclophosphamide in relapsed neuroblastoma: pharmacological rationale and clinical response.

Donfrancesco A, De Ioris MA, McDowell HP, De Pasquale MD, Ilari I, Jenkner A, Castellano A, Cialfi S, De Laurentis C, Dominici C.

Pediatr Blood Cancer. 2010 Jan;54(1):55-61. doi: 10.1002/pbc.22219.

PMID:
19821523
6.

Phase I trial of oral fenretinide in children with high-risk solid tumors: a report from the Children's Oncology Group (CCG 09709).

Children's Oncology Group (CCG 09709), Villablanca JG, Krailo MD, Ames MM, Reid JM, Reaman GH, Reynolds CP.

J Clin Oncol. 2006 Jul 20;24(21):3423-30. Erratum in: J Clin Oncol. 2006 Sep 1;24(25):4223. Reynolds, Patrick C [corrected to Reynolds, C Patrick].

PMID:
16849757
7.

Retrospective analysis of weekly topotecan as salvage therapy in relapsed ovarian cancer.

Bhoola SM, Coleman RL, Herzog T, Morris R, Bryant C, Estes JM, Alvarez RD.

Gynecol Oncol. 2004 Dec;95(3):564-9.

PMID:
15581964
8.

Efficacy of low-dose topotecan in second-line treatment for patients with epithelial ovarian carcinoma.

Gronlund B, Hansen HH, Høgdall C, Engelholm SA.

Cancer. 2002 Oct 15;95(8):1656-62.

9.

Phase I trial and pharmacokinetic (PK) and pharmacodynamics (PD) study of topotecan using a five-day course in children with refractory solid tumors: a pediatric oncology group study.

Tubergen DG, Stewart CF, Pratt CB, Zamboni WC, Winick N, Santana VM, Dryer ZA, Kurtzberg J, Bell B, Grier H, Vietti TJ.

J Pediatr Hematol Oncol. 1996 Nov;18(4):352-61.

PMID:
8888741
10.

Topotecan in the treatment of refractory neuroblastoma and other malignant tumors in childhood - a phase-II-study.

Längler A, Christaras A, Abshagen K, Krauth K, Hero B, Berthold F.

Klin Padiatr. 2002 Jul-Aug;214(4):153-6.

PMID:
12165894
11.

Topotecan in pediatric patients with recurrent and progressive solid tumors: a Pediatric Oncology Group phase II study.

Nitschke R, Parkhurst J, Sullivan J, Harris MB, Bernstein M, Pratt C.

J Pediatr Hematol Oncol. 1998 Jul-Aug;20(4):315-8.

PMID:
9703003
12.

Phase II trial of topotecan administered as 72-hour continuous infusion in children with refractory solid tumors: a collaborative Pediatric Branch, National Cancer Institute, and Children's Cancer Group Study.

Blaney SM, Needle MN, Gillespie A, Sato JK, Reaman GH, Berg SL, Adamson PC, Krailo MD, Bleyer WA, Poplack DG, Balis FM.

Clin Cancer Res. 1998 Feb;4(2):357-60.

13.

Phase I study of topotecan administered as a 21-day continous infusion in children with recurrent solid tumors: a report from the Children's Cancer Group.

Frangoul H, Ames MM, Mosher RB, Reid JM, Krailo MD, Seibel NL, Shaw DW, Steinherz PG, Whitlock JA, Holcenberg JS.

Clin Cancer Res. 1999 Dec;5(12):3956-62.

14.

The use of continuous infusion topotecan in persistent and recurrent ovarian cancer.

Elkas JC, Holschneider CH, Katz B, Li AJ, Louie R, McGonigle KF, Berek JS.

Int J Gynecol Cancer. 2003 Mar-Apr;13(2):138-41.

PMID:
12657113
15.

Oral topotecan given once or twice daily for ten days: a phase I pharmacology study in adult patients with solid tumors.

Gerrits CJ, Burris H, Schellens JH, Eckardt JR, Planting AS, van der Burg ME, Rodriguez GI, Loos WJ, van Beurden V, Hudson I, Fields S, Von Hoff DD, Verweij J.

Clin Cancer Res. 1998 May;4(5):1153-8.

16.

Duration of chemotherapy with topotecan influences survival in recurrent ovarian cancer: a meta-analysis.

Möbus V, Kieback DG, Kaubitzsch SK.

Anticancer Res. 2007 May-Jun;27(3B):1581-7.

17.

Phase I and pharmacokinetic study of topotecan administered orally once daily for 5 days for 2 consecutive weeks to pediatric patients with refractory solid tumors.

Daw NC, Santana VM, Iacono LC, Furman WL, Hawkins DR, Houghton PJ, Panetta JC, Gajjar AJ, Stewart CF.

J Clin Oncol. 2004 Mar 1;22(5):829-37.

PMID:
14990638
18.

Phase II study of temozolomide in combination with topotecan (TOTEM) in relapsed or refractory neuroblastoma: a European Innovative Therapies for Children with Cancer-SIOP-European Neuroblastoma study.

Di Giannatale A, Dias-Gastellier N, Devos A, Mc Hugh K, Boubaker A, Courbon F, Verschuur A, Ducassoul S, Malekzadeh K, Casanova M, Amoroso L, Chastagner P, Zwaan CM, Munzer C, Aerts I, Landman-Parker J, Riccardi R, Le Deley MC, Geoerger B, Rubie H.

Eur J Cancer. 2014 Jan;50(1):170-7. doi: 10.1016/j.ejca.2013.08.012. Epub 2013 Sep 7.

PMID:
24021349
19.

Efficacy and toxicity of weekly topotecan in recurrent epithelial ovarian and primary peritoneal cancer.

Safra T, Menczer J, Bernstein R, Shpigel S, Inbar MJ, Grisaru D, Golan A, Levy T.

Gynecol Oncol. 2007 Apr;105(1):205-10. Epub 2007 Jan 18.

PMID:
17239430
20.

Sequential intraperitoneal topotecan and oral etoposide chemotherapy in recurrent platinum-resistant ovarian carcinoma: results of a phase II trial.

Sood AK, Lush R, Geisler JP, Shahin MS, Sanders L, Sullivan D, Buller RE, Sorosky JI.

Clin Cancer Res. 2004 Sep 15;10(18 Pt 1):6080-5.

Supplemental Content

Support Center